Ling-Fei Kong, Xiao-Juan Rong, Pan Yan, Tuo Qin, Xiao-Hui Zhang, Yu-Tong Kang, Bo Cheng, Wen-Ling Su, Tian-Le Gao, Cai Tie
State key laboratory Coal resources and Safe Mining, China University of Mining and Technology-Beijing, Beijing, China.
School of Chemical and Environmental Engineering, China University of Mining and Technology-Beijing, Beijing, China.
Front Pharmacol. 2023 Mar 2;14:1066643. doi: 10.3389/fphar.2023.1066643. eCollection 2023.
Current drugs do not provide an absolute cure or modify the course of asthma. Boriss extract (SXCF) has been used as Uyghur medicine for several years to treat bronchial asthma. However, very limited research has been conducted on the therapeutic mechanisms of SXCF. Disruptions in the metabolic network of lipid mediators (LMs) are closely linked to the development of asthma. Here, we explored the therapeutic mechanism of SXCF in asthma based on the metabolic network of LMs, aiming to contribute to the understanding of SXCF in asthma treatment at the molecular level. The UHPLC-MRM strategy was used for the quantitative detection of LMs in the lung tissue and in the peripheral circulatory system (serum). ELISA was used to detect IgE in serum and cytokines in BALF. The lung tissue sections were stained with H&E to observe the infiltration of inflammatory cells, and behavioural changes in mice were observed and recorded throughout the animal experiment. In contrast to the asthma group, the opposite result was observed in the SXCF groups, where the perturbed LMs metabolic network was partly restored in a dose-dependent manner with a significant elevation of anti-inflammatory metabolites, while pro-inflammatory lipids were decreased. As significant downregulation of IgE and pro-inflammatory cytokines was observed, IgE and cytokines analysis also supported the anti-inflammatory effects of SXCF. It was also noticed that SXCF treatment reduced the number of coughs and decreased the inflammatory cell infiltration around the bronchus in mice. These results suggested that SXCF has a significant ameliorative effect on ovalbumin (OVA)-induced asthma. The modulation of LMs is a possible underlying mechanism of the SXCF effects.
目前的药物并不能完全治愈哮喘或改变其病程。博瑞思提取物（SXCF）作为维吾尔族药物已用于治疗支气管哮喘数年。然而，关于SXCF治疗机制的研究非常有限。脂质介质（LM）代谢网络的紊乱与哮喘的发生密切相关。在此，我们基于LM代谢网络探讨了SXCF治疗哮喘的机制，旨在从分子水平上促进对SXCF治疗哮喘的理解。采用超高效液相色谱-多反应监测（UHPLC-MRM）策略对肺组织和外周循环系统（血清）中的LM进行定量检测。采用酶联免疫吸附测定（ELISA）检测血清中的免疫球蛋白E（IgE）和支气管肺泡灌洗液（BALF）中的细胞因子。用苏木精-伊红（H&E）对肺组织切片进行染色，观察炎性细胞浸润情况，并在整个动物实验过程中观察和记录小鼠的行为变化。与哮喘组相比，SXCF组出现了相反的结果，其中紊乱的LM代谢网络部分以剂量依赖的方式恢复，抗炎代谢物显著升高，而促炎脂质减少。由于观察到IgE和促炎细胞因子显著下调，IgE和细胞因子分析也支持了SXCF的抗炎作用。还注意到SXCF治疗减少了小鼠的咳嗽次数，并减少了支气管周围的炎性细胞浸润。这些结果表明，SXCF对卵清蛋白（OVA）诱导的哮喘具有显著的改善作用。LM的调节可能是SXCF发挥作用的潜在机制。
